Skip to main content
search here
username password
Macmillan and Cancerbackup have merged. Together we provide free, high quality information for all.
How we produce our information|
This information is about a hormonal therapy called toremifene that is used to treat breast cancer. It should ideally be read with our general information about secondary breast cancer.
Toremifene is a hormonal therapy used to treat women with breast cancer who have had their menopause (change of life). It may be used to treat women whose cancer has spread to other areas of the body (secondary breast cancer).
Hormonal therapies interfere with the production or action of particular hormones in the body. Hormones are substances produced naturally in the body. They act as chemical messengers and help to control the activity of cells and organs.
The way in which toremifene works is not yet fully understood but its main function is as an anti-oestrogen drug. This means that it interferes with the action of the female hormone oestrogen.
Most breast cancers need supplies of the female sex hormone oestrogen to grow. Cancer cells have proteins called receptors on their surface that the sex hormones attach to. Cancers with oestrogen-receptors on the surface of their cells are called 'oestrogen-receptor-positive' (ER-positive) and toremifene is most effective against these cancers.
Under normal circumstances, when oestrogen comes into contact with the receptors it fits into them and activates the cancer cells to divide so that the tumour grows.
Toremifene fits into the oestrogen receptor but does not activate the cells to divide. The toremifene remains in place and prevents oestrogen from reaching the cancer cells so that they either grow more slowly or stop growing altogether.
Toremifene is a tablet that is taken once daily. It should be taken at approximately the same time each day.
Each person's reaction to any medication is different. Many women who take toremifene have no side effects, while others will experience them. We have outlined the most common side effects so that you can be aware of them if they occur. However, we have not included those that are very rare, and which are therefore extremely unlikely to affect you. If you notice any effects that you think may be due to the drug, but which are not listed in this information, please discuss them with your doctor or nurse.
You will see your doctor regularly while you have this treatment so that they can monitor the effects. This information should help you to discuss any queries about your treatment and its side effects with your doctor or nurse, who are in the best position to help and advise you.
Some women may have some of the following:
Hot flushes and sweats Sometimes the flushes will gradually lessen over the first few months but some women continue to have them for as long as they take toremifene.
There are a number of ways to help to reduce or control hot flushes and sweats. Some women find it helpful to avoid or cut down on tea, coffee, nicotine and alcohol. Drugs, including low doses of some antidepressants or progesterone, may be helpful in controlling this side effect. Your nurse or doctor can discuss this with you. Some women find that complementary therapies| help. Your GP may be able to give you details about obtaining these on the NHS.
Nausea and indigestion Feelings of sickness (nausea)| and indigestion are fairly common but can often be relieved by taking your tablet(s) with food or milk or at night. Although nausea is quite common initially, it usually wears off after a few weeks.
Thrombosis (blood clots) This is very rare. Signs of a thrombosis include pain, warmth, swelling or tenderness in an arm or leg, or chest pain. Any of these signs must be reported to your doctor immediately. Toremifine isn't usually given to people who have had a blood clot.
Vaginal bleeding or discharge Let your doctor know if you have any vaginal bleeding or discharge.
Vision problems Blurred or reduced vision is uncommon but let your doctor know about any changes to your eyesight.
Tumour flare Women who are prescribed toremifene for advanced cancer, where it has spread to the bones, may experience something called tumour flare when they start taking toremifene. This can cause a raised level of calcium in the blood (hypercalcaemia) with symptoms of nausea, vomiting and thirst. A short stay in hospital is very occasionally necessary until the calcium levels have been reduced.
Studies have shown that women who take high doses of toremifene over a long period of time may have a very slightly increased risk of developing cancer of the lining of the womb (endometrial cancer).
However, this small risk is generally outweighed by the benefits of taking toremifine. If detected early, treatment for endometrial cancer is usually very successful. An early warning sign is abnormal vaginal bleeding, although this is often caused by non-cancerous conditions such as polyps. If you have any abnormal vaginal bleeding, you should let your doctor know.
However, this risk has to be weighed against the benefits of toremifene in treating the breast cancer, which generally far outweigh the small risk of womb cancer. If detected early, treatment for endometrial cancer is usually very successful. Early warning signs are abnormal vaginal bleeding – although this is often caused by non-cancerous conditions such as polyps. If you have any abnormal vaginal bleeding you should let your doctor know.
In some cancer hospitals, women are given regular gynaecological check-ups to detect signs of endometrial cancer. An ultrasound scan, using sound waves, may be done to check for signs of change in the womb lining. A small probe is inserted into the vagina and the doctor can look at the scan on a screen. Any changes can be seen straight away. The scan is safe and only takes a few minutes.
There is little doubt that for most women the beneficial effects of toremifene far outweigh the risks.
Toremifene may interact with other medicines. Let your doctor know about any medications you are taking, including non-prescribed drugs such as complementary therapies and herbal drugs.
This section has been compiled using information from a number of reliable sources including:
British National Formulary (56th edition). British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2008.
For further references, please see the general bibliography|.
Posted by bob jk
Posted by GRAEME.
Posted by 'Bad Year' is now a 'Good Year'
If you have any questions about cancer, need support or just want someone to talk to, ask Macmillan.
Browser does not support script.